From Prescription to Effective Treatment: The Clinical Role of STHA
The management of sleep apnea does not end with diagnosis or prescription. In fact, the most critical phase begins once the patient returns home with a CPAP device. At this stage, numerous factors can compromise treatment effectiveness: discomfort with the mask, technical issues, insufficient patient education, or simply a lack of follow-up.
STHA intervenes precisely at this junction. It transforms what is traditionally a fragmented process into a continuous care pathway. By ensuring correct device installation, individualized mask fitting, and patient education in the home environment, STHA directly addresses the primary causes of non-adherence. This is particularly important given that adherence thresholds—typically defined as at least four hours of nightly use—are necessary to achieve meaningful clinical benefit.
Beyond the initial setup, STHA contributes to long-term disease control through regular follow-up and remote monitoring. Modern CPAP devices generate detailed data on usage patterns, residual apnea-hypopnea index, mask leakage, and pressure settings. When integrated into an STHA model, these data allow early identification of suboptimal therapy and timely corrective action, effectively extending the clinician’s reach beyond the sleep laboratory.
A Regulatory Framework Built Around Patient Safety
The deployment of CPAP therapy in the home setting is not only a clinical issue but also a regulatory one. Within the European Union, all medical devices, including CPAP systems, are governed by the Medical Device Regulation (EU) 2017/745, which establishes a comprehensive framework covering the entire lifecycle of a device—from design and manufacturing to post-market surveillance.
In practical terms, this means that a CPAP device used in sleep apnea must bear a CE marking, indicating compliance with stringent safety and performance requirements. However, regulatory expectations do not end at the moment the device is placed on the market. The MDR explicitly adopts a lifecycle approach, requiring ongoing data collection and vigilance to ensure that devices remain safe under real-world conditions.
This is where STHA acquires a crucial regulatory dimension. By maintaining close contact with patients and monitoring device performance in everyday use, STHA contributes directly to the post-market surveillance obligations imposed by the MDR. It effectively becomes part of the system through which real-world clinical data are generated and safety signals are detected.
While the MDR applies uniformly across the European Union, its implementation is overseen at the national level by competent authorities. Belgium has complemented the MDR with national legislation, notably the Law of 22 December 2020 on medical devices and several Royal Decrees adopted in 2021 to operationalize the European framework. These legal instruments define how European rules are enforced in practice, including registration requirements, market surveillance activities, and vigilance procedures.
STHA Providers as Regulated Actors
From a regulatory standpoint, organizations delivering STHA services are not neutral intermediaries. They are considered as distributors under the MDR framework. A distributor is defined as any entity that makes a medical device available on the market, up to the point at which it is put into service for the end user.
This classification entails a number of obligations. STHA providers must ensure that the devices they deliver are CE-marked, accompanied by appropriate documentation, and handled in accordance with the manufacturer’s instructions. They must also maintain records of complaints and incidents and cooperate with both manufacturers and regulatory authorities in case of safety issues. STHA actors involved in the installation, maintenance, and removal of medical devices used for sleep apnea outside the hospital fall under Articles 59 and 60 of the Belgian Law of 15 December 2013 and since November 2024, must comply with a mandatory self‑checking (autocontrol) system, as described in an official FAMHP‑approved guide.
Home Care, Risk Management, and Real-World Evidence
The use of CPAP devices in a home environment introduces specific risks that differ from those encountered in clinical settings. Improper mask fitting, inadequate cleaning, or incorrect device settings can compromise both the safety and effectiveness of therapy. The MDR explicitly recognizes the importance of addressing such risks, particularly for devices intended for use by non-professionals.
STHA mitigates these risks by ensuring that patients are properly trained and supported. The presence of trained personnel during the initial setup significantly reduces the likelihood of misuse, while ongoing monitoring allows early detection of problems such as excessive mask leakage or insufficient adherence.
From a regulatory perspective, this continuous interaction generates valuable real-world evidence. The MDR requires manufacturers to conduct post-market clinical follow-up, collecting data on device performance in routine use. STHA providers, through their direct contact with patients and access to usage data, contribute to this requirement by acting as intermediaries between patients, clinicians, and manufacturers.
Digitalization and the Future of Compliance
The increasing digitalization of CPAP therapy further reinforces the role of STHA. Connected devices enable remote monitoring and data sharing, facilitating proactive care management. At the same time, European regulatory systems are evolving to integrate these capabilities.
A key development in this regard is the progressive implementation of EUDAMED, the European database for medical devices. From May 28, 2026, several of its modules, including those related to economic operator registration and device identification, will become mandatory. This will enhance transparency and traceability across the European market.
For STHA providers, this evolution implies the need to integrate digital traceability systems into their operations. Managing device identifiers, ensuring accurate patient-device linkage, and supporting regulatory reporting will become essential components of service delivery.
Conclusion
STHA represents a significant evolution in the management of sleep apnea, combining clinical support, technical expertise, and regulatory compliance into a unified model of care. By extending medical supervision into the patient’s home, it addresses one of the most critical challenges in sleep medicine: ensuring long-term adherence to therapy.
At the same time, STHA aligns closely with the requirements of the European Medical Device Regulation and the oversight mechanisms of national authorities such as the FAMHP. It contributes to post-market surveillance, supports vigilance systems, and enhances the safe use of medical devices in real-world conditions.
In this sense, STHA should not be viewed as an optional add-on, but as an integral component of modern, regulation-compliant sleep apnea care—one that bridges the gap between technological innovation, clinical practice, and patient-centered outcomes.